

ORIGINAL ARTICLE

CALCIUM DOBESILATE IN SYMPTOMATIC TREATMENT OF HEMORRHOIDAL DISEASE: AN INTERVENTIONAL STUDY

Hiteshkumar D Patel¹, Amul N Bhedi¹, Asutosh P Chauhan², Rachit M Joshi³

¹Assistant Professor, Department of Surgery, Govt. Medical College, Baroda; ²Assistant Professor, Department of Biochemistry, Govt. Medical College, Baroda; ³Assistant Professor, Department of Physiology, GMERS, Gandhinagar

Correspondence: Hiteshkumar D Patel, Email: Hitesh_315@yahoo.co.in

ABSTRACT

Introduction: Hemorrhoidal disease is one of the commonest ailments that affects mankind and is currently believed to be caused by distal displacement and structural distortion of anal cushions, which are physiologic structures. A randomized, double blind, controlled study was conducted to investigate the efficacy of oral and local calcium dobesilate therapy in treating acute attacks of internal hemorrhoids.

Methods: fifty nine (59) adult patients with first or second-degree internal hemorrhoids were treated with calcium dobesilate for six weeks, while 56 patients received only a high fiber diet to serve as control. Both symptoms and anoscopic inflammation were scored on a scale from 0 to 2 before and six weeks after treatment.

Results: A success rate of 83.05% percent with cessation of bleeding plus lack of severe anitis anoscopically at 6 weeks were achieved with calcium dobesilate. The pretreatment symptoms score of 2 were fell significantly to 0.39 ± 0.16 and the pretreatment anitis score of 1.73 ± 0.12 fell to 0.59 ± 0.17 at 6 weeks ($p=0.0002$ for both comparisons). The symptoms and anoscopic inflammation score obtained with calcium dobesilate therapy were also significantly better than those with diet only. ($P=0.0016$ and $p=0.0014$, respectively).

Conclusions: oral as well as local calcium dobesilate treatment supplemented with diet and bowel habits discipline provides an effective, fast, and safe symptomatic relief from acute symptoms of Hemorrhoidal disease. This symptomatic relief is associated with significant improvement in anoscopically observed inflammation.

Keywords: Calcium dobesilate, hemorrhoidal disease

INTRODUCTION

Hemorrhoidal disease is one of the commonest ailments that affects mankind and is currently believed to be caused by distal displacement and structural distortion of anal cushions, which are physiologic structures.¹ Anatomic studies have revealed that the anchoring and supporting sub epithelial tissue deteriorates with aging, and the descended loose lining becomes more sensitive to trauma from stool, occasionally resulting in venous distention, inflammation, erosion, bleeding, and/or thrombosis.^{3,4} the finding of proctoscopic anitis which correlates with enlarged lamina propria, capillaries with inflammation, is associated with occurrence of hemorrhoidal bleeding and/or pain.^{4,5,11}

The treatment can be grouped into conservative (diet and vascular tonification), nonexcision (sclerotherapy, cryotherapy, manual anal dilatation, diathermy and electro coagulation) and surgical methods (ligation and hemorrhoidectomy).^{1,2,7} extent of mucosal fixation by injection sclerotherapy, infrared photocoagulation, or band ligation almost never reaches to that of surgical hemorrhoidectomy, most of these alternative fixation

methods can be performed in opd basis without anesthesia, and more than 90 percent of symptoms can be successfully controlled by such nonexcisional techniques with fewer complications and pain, compared with hemorrhoidectomy.^{7, 13} More conservative policy is based on the current data that hemorrhoids are normal anatomic structure and age related structural changes occur in every person, whereas symptoms develop in some people.^{3,4} Calcium dobesilate (calcium 2,5 dihydroxybenzenesulfonate) is a drug with previously demonstrated efficacy in the treatment of diabetic retinopathy and chronic venous insufficiency.^{8,9,12}

These beneficial effects of the drug are related to its ability to decrease capillary permeability, platelet aggregation and blood viscosity and to increase lymphatic transport. Because these properties would reasonably be expected to contribute to the acute inflammatory attacks of hemorrhoidal disease, this randomized, double blind study was conducted to investigate the efficacy of calcium dobesilate in treating acute attacks of hemorrhoidal disease, based on objective healing and subjective/symptomatic criteria.⁶

METHODS

Total of 115 adult patients with first and second-degree hemorrhoids diagnosed by clinical symptoms and anoscopy examination are included in this study.

Inclusion Criteria: in all patients, intermittent symptoms attributable to hemorrhoids had existed for longer than six months and rectal bleeding was currently present. Hemorrhoids that bleed but do not prolapse outside the anal canal (bulge into the lumen of the proctoscope) are labeled as first degree hemorrhoids and that prolapse on defecation but reduce spontaneously or can be reduced digitally and remain reduced labeled as second degree hemorrhoids.

Exclusion Criteria: 1.patients with 3 or 4 hemorrhoids in whom prolapse needed manual reduction or was not reducible

2.concurrent fistula or chronic anal fissure, inflammatory bowel disease, diabetes, coagulation disorders, abnormal sexual habits, previous anorectal surgery or previous treatment of hemorrhoid disease with any method other than diet modification and/or topical agents. Rectosigmoidoscopy and barium enema (if indicated) was included in workup to rule out colorectal cause of symptoms.

Ethical approval was obtained from the university ethical committee. Written informed consent was taken from all patients.

After initial anoscopy examination at entry day the patients were randomly allotted by envelope method to enter study or control group.

Group A (control group n=56): diet manipulation and lifestyle advice.

Group B (calcium dobesilate n=59) after initial anoscopy examination, calcium dobesilate capsule (500 mg) was given in the dosage of two capsule twice a day for one week and one capsule for once a day for 5 weeks and calcium dobesilate ointment (0.5%w/w) was applied twice a day before and after defecation. The therapy was given for six weeks and each case examined after every week to see the improvement or otherwise of various symptoms associated with hemorrhoids. The patients also received dietary and lifestyle advice, as did patients in the control group.

Diet manipulation: a high fiber diet was advised to all patients in both groups and educated about importance of fiber (fruits, vegetables etc.) in healthy nutrition. Heavy consumption of spices was also not allowed. Encouragement was given to correct unhealthy defecation habits such as ignoring the need to pass stools, irregular meals, straining and lack of exercise.

Patient follow up and evaluation of healing: the patients were reexamined on every weekly. If symptomatic relief was achieved the day of relief from symptoms was recorded. Score as follows: 0=significant relief or lack of any symptoms, 1=partial relief of symptoms –minor complaints with no bleeding or 2=no

relief and/or persistent rectal bleeding. Anoscopy examination performed on every weekly and score as follows: 0=pink, healthy mucosa without any sign of inflammation, 1=mild anitis (inactive grade 2 hemorrhoid without overt inflammatory signs or 2=easily bleeding hemorrhoids with signs of inflammation. For patients with more than one hemorrhoid the worst lesion was considered for outcome. If bleeding persist for more than two weeks after starting of either therapy and/or anitis score 2 was noted at 2 weeks this regarded as treatment failure. If mild anitis with cessation of bleeding was noted at 2 weeks then calcium dobesilate was continue for two more weeks and patients were advised to come immediately if they develop symptoms. Any recurrent bleeding was evaluated by anoscopy and colonoscopy examination and consider as recurrent of hemorrhoids disease if no other source of bleeding found.

RESULTS AND DATA ANALYSIS

Calcium dobesilate therapy was carried out in 59 cases and diet therapy in 56 cases. 35 patients in diet control group were male and median age was 44 years (range, 22-64). In calcium dobesilate group 39 patients were male and median age of 46 (range 26-68). All of the patients had current rectal bleeding. Duration of rectal bleeding varied from 1 month to 3 years. The anitis scores of group A and group B at entry were also comparable (1.70 ± 0.14 and 1.73 ± 0.12 respectively, $p=0.66$).

Table 1 showing presenting symptoms:

Symptoms	Patients (%)
Bleeding per rectum	115 (100)
Anal pain	38 (33)
Anal discomfort	29 (25)
Anal pruritus	46 (40)
Tenesmus	22 (19)
Constipation/irregular bowel habits	86 (75)

Group A: After 6 weeks of diet therapy, symptoms score in group A (1.34 ± 0.19 ; $p=0.023$) was noted. 16 patients were symptoms free and 8 patients were declared partial relief. 32 (57.14%) of the 56 patients still had rectal bleeding and anitis score after 6 weeks reached at 1.34 ± 0.22 vs. 1.70 ± 0.14 at entry $p=0.0439$. the results are shown in table 2.

Group B: after 6 weeks of calcium dobesilate therapy, cessation of rectal bleeding plus lack of severe anitis occur in 48 patients indicating success rate of 81.35% $p=0.0051$ compared with 44% rate of control group. Time of significant relief from symptoms averaged 6.5 days range (2- 12 days) post treatment anitis score (0.59 ± 0.17) was significantly better than the pretreatment anitis score (1.73 ± 0.12 , $p=0.0003$) as well as posttreatment score of the control group (1.34 ± 0.22 ; $p=0.0013$). There was no toxic or untoward reaction to the capsule and ointment during study period.

Table 2: symptomatic and anosopic score and success rate of group A (diet) and group B (study)

Group	Symptoms score		Anitis score		Success rate
	Before treatment	after treatment	Before treatment	after treatment	
A-diet (n=56)	2	1.34±0.19	1.70±0.14	1.34±0.22	42.85%
B-study (n=59)	2	0.51±0.11	1.73±0.12	0.59±0.17	84.75%

Table 3: Symptoms and Anitis score of Group A (control) and group B (study)

Scores	Group A (n=56) (%)	Group B (n=59) (%)
Symptoms score before treatment		
0	-	-
1	-	-
2	56(100)	59(100)
Symptoms score after treatment		
0	16(28.57)	40(67.79)
1	8(14.28)	10(16.94)
2	32(57.14)	9(15.25)
Anitis score before treatment		
0	-	-
1	17(30.35)	16(27.11)
2	39(69.64)	43(72.88)
Anitis score after treatment		
0	8(12.28)	33(55.93)
1	25(44.64)	23(38.98)
2	23(41.07)	3(5.08)

DISCUSSION

Calciumdobesilate treatment appear to be highly effective in controlling bleeding per rectum in hemorrhoidal disease. 50 (84.74%) of 59 patients were noted to be symptoms free or significantly improved with complete cessation of bleeding as reflected by significant difference between symptoms scores before and two weeks after treatment=0.0002. Symptoms as well objective anitis scores were significantly better in study group. The time of relief from symptoms in 84.75% of cases averaged 6.5 days. In our out patients department 1 and 2 degree hemorrhoidal disease are common so included in our study however advanced hemorrhoidal disease (3 and 4 degree) might also benefited from this drug although severe structural degeneration changes might required corrective surgery. Daily intake of dietary fiber and bowel habits were monitored during follow up visits and encouragement was given to correct other causes of constipation such as ignoring need to pass stools, irregular meals. As per patient history, the amount of fiber in diet is sufficient to increase colonic peristalsis and bulky stool and thus regular bowel habits, however this parameter were not investigated.^{14, 15} After dietary advice 81.73%(94/115) patients had soft bulky stool and regular bowel habits. Before treatment it was 25%. As per this study results, the success rate of diet group seems to be unsatisfactory (42.85%) and dietary therapy alone is not effective in treatment of hemorrhoidal diseases but should be used as adjuvant with any primary treatment modality.

However we cannot evaluate long term result in form of recurrence because of short term follow up period.

CONCLUSION

Calciumdobesilate treatment supplemented with high fiber diet is highly effective in symptomatic acute attacks of 1 and 2 degree internal hemorrhoids. This improvement is superior to that obtained in control diet group without any noticeable side effects. However further data required for long-term course of patients with this drug.

REFERENCE:

1. R C G Russell, Norman S, Williams, Christopher. Bailey and love: short practice of surgery, international student's edition 23ed edition. The anus and anal canal page no: 1128-1134
2. Michael J. Zinner, Seymour I. Schwartz, Harold Ellis. Maingot's abdominal operation, international edition 10th edition benign diseases of the anorectum page no 1440-1444.
3. Loder PB, Karoto MA, Nichollos RJ. Haemorrhoids: pathology, pathophysiology and aetiology. Br J Surg 1994; 81:946-54
4. Haas PA, Haas GP, Fox TA. The pathogenesis of hemorrhoids. Dis Colon Rectum 1984; 27:442-50
5. Thomson WH. The nature of haemorrhoids. Br J Surgery 1975; 62:542-552
6. Menten BB, Gorgul A. Efficacy of calciumdobesilate in treating acute attacks of hemorrhoidal disease. Dis Colon Rectum 2001; 44:1489-1495
7. Eisenstat T, Selvati EP, Rubin RJ. The outpatient management of acute hemorrhoidal disease. Dis Colon Rectum 1979; 22:315-317
8. Angem F. Efficacy and safety of calciumdobesilate in patients with chronic venous insufficiency: an open label multicenter study. Curr Ther Res 1995; 56:346-357
9. Casley-smith JR. A double-blind trial of calciumdobesilate in chronic venous insufficiency. Angiology 1988; 39:853-857
10. Godeberge P. Daflon 500 mg in treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo. Angiology 1994; 45:574-580.
11. Williams NS. Hemorrhoidal disease. In: Keighly MR, Williams NS, Eds. Surgery of the anus, rectum and colon. Philadelphia: WB Saunders, 1993:295-363
12. Barras JP, Michal M. Effect of calciumdobesilate on blood viscosity in diabetic microangiopathy: a review. Vasa 1986; 15:200-205
13. MacRae HM, McLeod RS. Comparison of hemorrhoidal treatments: a meta-analysis. Can J Surg 1997; 40:14-17
14. Englyst HN, Qitely ME, Hudson GJ. Definition and measurement of dietary fiber. Eur J Clin Nutr 1995; 49(suppl 3): 548 Cummings JH. Constipation, dietary fibre and the control of large bowel function. Postgrad Med J 1984; 60:811-819